Articles from Caixin Global, Caixin Global

Caixin Global

Articles from Caixin Global

Caixin is a media group dedicated to providing financial and business news through periodicals, online content, mobile apps, conferences, books and TV/video programs. Caixin aims to blaze a trail that helps traditional media prosper in the new media age through integrated multimedia platforms.

News from Caixin

Cross Asset Strategy

<ul><li>Robots /In Depth: The march of Chinese robots into domestic factories</li><li>Dam /: China expresses ‘grave concerns’ over Ukraine dam collapse</li><li>Compensation /: Wrongfully convicted man seeks $2.9 million in state compensation</li></ul>

Robots /In Depth: The march of Chinese robots into domestic factoriesDam /: China expresses ‘grave concerns’ over Ukraine dam collapseCompensation /: Wrongfully convicted man seeks $2.9 million in state compensation

CX Daily: The March of Chinese Robots Into Domestic Factories

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>It is the time to reassess the commercialization performance and the outlook of China biotech companies, including BeiGene, Innovent, Henlus, Zai Lab, Hutchmed, Junshi, RemeGen, Innocare, Akeso. </li>
<li>We summarized the data of these biotech companies’ product revenue and profit performance to judge whether their commercialization capability is sufficient to afford production, sales teams and long-term R&amp;D activities. </li>
<li>Most China Biotech cannot be said to achieve "commercialization success", but they have showed some difference.We hope investors could have a better understanding about China biotech and make better decisions. </li>
</ul>


It is the time to reassess the commercialization performance and the outlook of China biotech companies, including BeiGene, Innovent, Henlus, Zai Lab, Hutchmed, Junshi, RemeGen, Innocare, Akeso. 
We summarized the data of these biotech companies’ product revenue and profit performance to judge whether their commercialization capability is sufficient to afford production, sales teams and long-term R&amp;D activities. 
Most China Biotech cannot be said to achieve "commercialization success", but they have showed some difference.We hope investors could have a better understanding about China biotech and make better decisions. 


China Biotech – The Commercialization Performance and The Outlook

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Gland Pharma posted a record Q4 FY26 with revenue up 22% and adjusted PAT up 97% YoY, powered by CDMO and a turning-profitable Cenexi.</li>
<li>CDMO now contributes 46% of quarterly revenue at 36% growth, shifting Gland from a US-generics price-taker toward a higher-margin, stickier outsourcing model.</li>
<li>With the stock trading near 36 to 41 times earnings, the next two to three quarters of execution will decide whether this rerating holds.</li>
</ul>


Gland Pharma posted a record Q4 FY26 with revenue up 22% and adjusted PAT up 97% YoY, powered by CDMO and a turning-profitable Cenexi.
CDMO now contributes 46% of quarterly revenue at 36% growth, shifting Gland from a US-generics price-taker toward a higher-margin, stickier outsourcing model.
With the stock trading near 36 to 41 times earnings, the next two to three quarters of execution will decide whether this rerating holds.


Gland Pharma: The CDMO Growth Engine Takes the Steering Wheel

<ul>
<li>
Caixin Explains: Washington’s drive to hobble Chinese chipmaking
</li>
<li>
Communist Party’s 20th National Congress to kick off on Oct. 16
</li>
<li>
Shenzhen schools delay fall term as city braces for fresh Covid outbreak
</li>
</ul>



Caixin Explains: Washington’s drive to hobble Chinese chipmaking


Communist Party’s 20th National Congress to kick off on Oct. 16


Shenzhen schools delay fall term as city braces for fresh Covid outbreak



CX Daily: Washington’s Drive to Hobble Chinese Chipmaking

<ul>
<li>China approved the first self-developed COVID-19 oral drug (Azivudine), but there are controversies about efficacy and safety profile on it, which could increase the unpredictability of domestic innovative drugs approval.</li>
<li>Due to the VBP, fierce competition, uncertainties in the COVID-19 prevention/control policies and decreasing demand, the commercialization performance and outlook of Azivudine could be lower-then-expected in China and overseas markets.</li>
<li>The approval of Azivudine wouldn’t change the zero-COVID policy. Until President Xi’s third term appointment is confirmed, there’s no reason to expect China to deviate from this policy.</li>
</ul>


China approved the first self-developed COVID-19 oral drug (Azivudine), but there are controversies about efficacy and safety profile on it, which could increase the unpredictability of domestic innovative drugs approval.
Due to the VBP, fierce competition, uncertainties in the COVID-19 prevention/control policies and decreasing demand, the commercialization performance and outlook of Azivudine could be lower-then-expected in China and overseas markets.
The approval of Azivudine wouldn’t change the zero-COVID policy. Until President Xi’s third term appointment is confirmed, there’s no reason to expect China to deviate from this policy.


Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?

China

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company. Through its subsidiaries, the Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services, as well as invests in import and export trading.

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

CX Daily: The March of Chinese Robots Into Domestic Factories

Robots /In Depth: The march of Chinese robots into domestic factories Dam /: China expresses ‘grave concerns’ over Ukraine dam...

Caixin Global

China Biotech – The Commercialization Performance and The Outlook

In the context of the fading dividend of medical system reform and the lack of next big variety, the previous wave of innovative drug boom is hard...

Xinyao (Criss) Wang

Gland Pharma: The CDMO Growth Engine Takes the Steering Wheel

Gland Pharma's strong Q4 performance driven by CDMO and profitable Cenexi, shifting towards higher-margin outsourcing model. Stock valuation...

Nimish Maheshwari

CX Daily: Washington’s Drive to Hobble Chinese Chipmaking

Caixin Explains: Washington’s drive to hobble Chinese chipmaking. Communist Party’s 20th National Congress to kick off on Oct. 16

Caixin Global

Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?

Due to VBP/fierce competition/weak demand, Azivudine's outlook is challenging.Until President Xi’s 3rd term appointment is confirmed,there’s no...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

CX Daily: The March of Chinese Robots Into Domestic Factories

Robots /In Depth: The march of Chinese robots into domestic factories Dam /: China expresses ‘grave concerns’ over Ukraine dam...

Caixin Global

China Biotech – The Commercialization Performance and The Outlook

In the context of the fading dividend of medical system reform and the lack of next big variety, the previous wave of innovative drug boom is hard...

Xinyao (Criss) Wang

Gland Pharma: The CDMO Growth Engine Takes the Steering Wheel

​Gland Pharma's strong Q4 performance driven by CDMO and profitable Cenexi, shifting towards higher-margin outsourcing model. Stock valuation...

Nimish Maheshwari

CX Daily: Washington’s Drive to Hobble Chinese Chipmaking

Caixin Explains: Washington’s drive to hobble Chinese chipmaking. Communist Party’s 20th National Congress to kick off on Oct. 16

Caixin Global

Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?

Due to VBP/fierce competition/weak demand, Azivudine's outlook is challenging.Until President Xi’s 3rd term appointment is confirmed,there’s no...

Xinyao (Criss) Wang

Gland Pharma's strong Q4 performance driven by CDMO and profitable Cenexi, shifting towards higher-margin outsourcing model. Stock valuation...